Hematopoiesis News Volume 7.17 | May 3 2016

Modeling BCR-ABL and MLL-AF9 Leukemia in a Human Bone Marrow-Like Scaffold Based Xenograft Model
Investigators observed that, in contrast to the murine bone marrow niche, expression of BCR-ABL or MLL-AF9 was sufficient to induce both primary AML and ALL. [Leukemia] Abstract

Ex Vivo Tools for the Clonal Analysis of Zebrafish Hematopoiesis
This protocol describes the ex vivo characterization of zebrafish hematopoietic progenitors. Researchers describe how to isolate individual colonies for further imaging and gene expression profiling. [Nat Protoc] Abstract

The Cyclin D1 Carboxyl Regulatory Domain Controls the Division and Differentiation of Hematopoietic Cells
Scientists showed that the cyclin D1 is indispensable for normal hematopoiesis. Indeed, in the absence of D1, either in genetic deficient mice, or after acute ablation by RNA interference, cyclins D2 and D3 are also not expressed preventing hematopoietic cell division and differentiation at its earliest stage. [Biol Direct] Full Article

FOXN1 Recombinant Protein Enhances T-Cell Regeneration after Hematopoietic Stem Cell Transplantation in Mice
To investigate the potential application of FOXN1, investigators have cloned and expressed recombinant FOXN1 protein that was fused with cell-penetrating peptides. [Eur J Immunol] Abstract

CLINICAL RESEARCH

CD19 CAR–T Cells of Defined CD4⁺:CD8⁺ Composition in Adult B Cell ALL Patients
Researchers conducted a clinical trial to evaluate CD19 CAR–T cells that were manufactured from defined CD4⁺ and CD8⁺ T cell subsets and administered in a defined CD4⁺:CD8⁺ composition to adults with B cell acute lymphoblastic leukemia after lymphodepletion chemotherapy. [J Clin Invest] Full Article

Dasatinib and Low-Intensity Chemotherapy in Elderly Patients with Philadelphia Chromosome-Positive ALL
Prognosis of Philadelphia-positive acute lymphoblastic leukemia in the elderly has improved during the imatinib era. The authors investigated dasatinib, another potent tyrosine kinase inhibitor, in combination with low-intensity chemotherapy. [Blood] Abstract

Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma in Europe: Trends and Outcomes over 25 Years: A Study by the EBMT CMWP
Investigators describe the use and outcomes of allogeneic hematopoietic stem cell transplantation for multiple myeloma in Europe between January 1990 and December 2012. [Leukemia] Abstract

CTLA-4 Polymorphisms and Haplotype Correlate with Survival in ALL after Allogeneic Stem Cell Transplantation from Related HLA-Haplotype-Mismatched Donor
Researchers focused on four CTLA-4 polymorphisms, and analyzed the impact of donor genotypes and haplotypes on the conditions of 152 acute leukemia patients after related HLA-haplotype- mismatched transplantation. [J Transl Med] Full Article

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

Stemline Therapeutics Clears First Cohort of Patients in Ongoing SL-801 Phase I Trial
Stemline Therapeutics, Inc. announced that it has completed the initial dosing cohort in its SL-801 Phase I advanced solid tumor trial. SL-801 is a novel, oral, small molecule that reversibly inhibits the XPO1 (Exportin-1) nuclear transport protein, a clinically validated target active in a wide variety of cancer types. [Stemline Therapeutics, Inc.] Press Release

From our sponsor:
Want to learn more about ALDH in breast cancer treatment response? Listen to the podcast.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the hematopoiesis community.

NEW Postdoctoral Fellow – Hematopoietic Stem Cell Biology and Blood Disorders (Brigham & Women’s Hospital)

NEW Research Technician – Hematopoietic Stem Cell Biology (Fred Hutchinson Cancer Research Center)

Scientist – Hematology (STEMCELL Technologies Inc.)

Postdoctoral Research Associate – Stem Cell Aging Biology (University of Southern California)

Engineering Project Lead (Cytonome)

Postdoctoral Fellow – Hematopoietic Stem Cells (University of Pennsylvania)

Postdoctoral Research Associate – Blood Stem Cell Microenvironment (University of Illinois)

Postdoctoral Fellow – Hematology/Oncology (Boston Children’s Hospital)

Assistant/Associate/Full Member Faculty – Myeloid Malignancies (Fred Hutchinson Cancer Research Center)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.